Roivant Sciences Ltd (FRA:87S)
€ 11.525 0.15 (1.32%) Market Cap: 8.62 Bil Enterprise Value: 3.56 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 60/100

Roivant Sciences Ltd at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 05:00PM GMT
Release Date Price: €8.95 (+5.29%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Great. Well, thanks to the team from Roivant that's here today. Richard Pulik, CFO; Mayukh Sukhatme, Chief Investment Officer.

Questions & Answers

Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

And maybe just to start, we can talk about kind of a brief overview of the business and what you view as key programs that will shape the story over the next 12 to 24 months?

Mayukh Sukhatme
Roivant Sciences Ltd. - President & CIO

Sure. Yes. So for those of you who may be less familiar with Roivant as a company or a public company, a little over $7 billion in market cap, a little less than $2 billion in cash. We have a marketed product in VTAMA and a series of late stage, mid late-stage clinical programs, including a first-in-class TL1A antibody, an FcRn portfolio via Immunovant, a TYK2 JAK1, and many, many other things.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot